Application of parallel liquid chromatography/mass spectrometry for high throughput microsomal stability screening of compound libraries  by Xu, Rongda et al.
Application of Parallel Liquid
Chromatography/Mass Spectrometry
for High Throughput Microsomal Stability
Screening of Compound Libraries
Rongda Xu, Csaba Nemes,* Kelly M. Jenkins, Robyn A. Rourick,
and Daniel B. Kassel
DuPont Pharmaceuticals Research Laboratories, San Diego, California, USA
Charles Z. C. Liu
Applied Biosystems, Foster City, California, USA
Solution-phase and solid-phase parallel synthesis and high throughput screening have
enabled biologically active and selective compounds to be identified at an unprecedented rate.
The challenge has been to convert these hits into viable development candidates. To accelerate
the conversion of these hits into lead development candidates, early assessment of the
physicochemical and pharmacological properties of these compounds is being made. In
particular, in vitro absorption, distribution, metabolism, and elimination (ADME) assays are
being conducted at earlier and earlier stages of discovery with the goal of reducing the attrition
rate of these potential drug candidates as they progress through development. In this report,
we present an eight-channel parallel liquid chromatography/mass spectrometry (LC/MS)
system in combination with custom Visual Basic and Applescript automated data processing
applications for high throughput early ADME. The parallel LC/MS system was configured
with one set of gradient LC pumps and an eight-channel multiple probe autosampler. The flow
was split equivalently into eight streams before the multiple probe autosampler and recom-
bined after the eight columns and just prior to the mass spectrometer ion source. The system
was tested for column-to-column variation and for reproducibility over a 17 h period
(approximately 500 injections per column). The variations in retention time and peak area were
determined to be less than 2 and 10%, respectively, in both tests. The parallel LC/MS system
described permits time-course microsomal incubations (to, t5, t15, t30) to be measured in
triplicate and enables estimations of t1/2 microsomal stability. The parallel LC/MS system is
capable of analyzing up to 240 samples per hour and permits the complete profiling up to two
microtiter plates of compounds per day (i.e., 176 test substrate compounds  sixteen
controls). (J Am Soc Mass Spectrom 2002, 13, 155–165) © 2002 American Society for Mass
Spectrometry
Advances in directed parallel synthesis and highthroughput screening (HTS) have enabled largenumbers of biochemically potent (active) and
selective compounds to be identified at early stages of
drug discovery [1–3]. However, the fact that a com-
pound is active and selective does not necessarily make
it an attractive drug development candidate. To convert
these lead candidates into druggable molecules has
proved elusive. It has been reported that a dispropor-
tionately large number of compounds entering devel-
opment fail because of poor pharmacokinetics (nearly
40%) [3–5]. Consequently, it has been recognized that
pharmacokinetic studies that assess absorption, distri-
bution, metabolism, and elimination (ADME) should be
initiated as early as possible in the discovery process in
order to maximize the likelihood of development suc-
cess and minimize development costs. More and more,
discovery programs are taking advantage of high
throughput in vitro assays and property-based design
tools to assist medicinal chemists in making not only
potent and selective compounds, but ADME-friendly
compounds as well [5].
The properties of absorption and metabolism have
received perhaps the greatest amount of attention at
early stages of discovery for the reason that oral dosing
is by far the preferred route of administration to treat
Published online December 3, 2001
Address reprint requests to Dr. D. B. Kassel, DuPont Pharmaceuticals
Research Labs, 4570 Executive Drive, Suite 400, San Diego, CA 92121, USA.
E-mail: daniel.b.kassel@dupontpharma.com
*Present address: 3M Pharmaceutical ARD, St. Paul, MN 55144, USA.
© 2002 American Society for Mass Spectrometry. Published by Elsevier Science Inc. Received August 23, 2001
1044-0305/02/$20.00 Revised October 10, 2001
PII S1044-0305(01)00342-7 Accepted October 10, 2001
chronic illnesses and diseases. As compounds are ad-
ministered orally, they are transferred across the intes-
tinal lumen (the process of oral absorption) into the
portal vein. Subsequently, these compounds are ex-
posed to the liver (the major organ of xenobiotic trans-
formation) prior to entering systemic circulation. It is in
the liver where the drug is subject to first pass effects.
The compound may be either a substrate for or an
inhibitor of the cytochrome P450 metabolizing enzymes
(i.e., the monooxidases primarily responsible for metab-
olizing xenobiotics). The extent to which a compound is
a substrate for these enzymes influences in part the
duration of action of the compound. Knowledge of the
inhibitory effect of a drug molecule on any one of the
key cytochrome P450 metabolizing enzymes is crucial to
prevent undesirable drug–drug interactions when
drugs are coadministered. Another very important rea-
son absorption and metabolism are acknowledged as
key properties to profile for at earlier stages of discov-
ery is that they are the most well established (experi-
mentally) and most well validated in vitro assays. In
particular, the in vitro microsomal stability assay has
been routinely used for the prediction of intrinsic clear-
ance [6], a key pharmacokinetic property influencing in
vivo half-life.
Liquid chromatography-mass spectrometry (LC/
MS) has become the preferred tool for in vitro ADME
screens because of its sensitivity, selectivity, versatility,
and ease of automation. Korfmacher et al. recently
described a fully automated system for quantitative
analysis of liver microsomal incubation samples incor-
porating LC/MS and automated data processing tools
[7]. Although their method was automated, sample
throughput was limited because of the relatively long
HPLC gradient analysis times (10 min per sample).
More recently, analysis throughput has been improved
by shortening the HPLC run time [8–11]. Samples can
be analyzed one at a time in as little as about one min
per sample by applying fast gradients with most state-
of-the-art LC/MS based techniques used to assess
ADME properties [8]. The cycle time may be reduced
further to less than one min when multiple autosam-
plers are used in concert to eliminate delays associated
with sample loading and when preanalysis extraction
and isocratic elution techniques are employed [10, 11].
However, in each of these single column systems, the
samples are processed in serial, ultimately limiting the
throughput and leaving little room for stretching the
hardware capabilities if higher throughput is required.
Pooling strategies have been incorporated as a
means for increasing throughput and reducing the total
number of samples to be analyzed. Stevenson et al.
demonstrated the power of this approach for the in
vitro cell permeability screening of compound libraries
[12]. Another approach is to dose multiple compounds
together, known as cassette dosing. Berman and co-
workers described how cassette dosing is applied to
rapid pharmacokinetic screening [13]. Pooling strate-
gies and cassette dosing are compromised principally
by sensitivity and solubility issues (the larger the num-
ber of compounds pooled, the lower the concentration
of each individual component possible) and the greater
the potential for synergistic and/or antagonistic effects.
Alternatively, multiple pharmacokinetic samples of an
individual compound across all time points may be
pooled before analysis [14].
A staggered injection and elution technique that uses
multiple columns in parallel and acquires data only in
the useful part of chromatograms can reduce overall
analysis time as well [15–17]. Houda and co-workers
recently demonstrated how fast LC/MS can be used to
increase metabolic screening analysis throughput [18]
by this method. This approach requires complex tubing
and valve switching schemes. The staggered injection
and elution method, although well suited to pharmaco-
kinetic studies, has not yet proven useful for combina-
torial library screening, where each member of the
library has a unique structure and a unique chromato-
graphic retention time.
True parallel approaches, on the other hand, are
showing promise for high throughput ADME screen-
ing. The parallel LC/MS methods allow multiple sam-
ples to be analyzed in parallel by injecting discrete
compounds onto multiple columns and detecting them
simultaneously in a single mass spectrometer ion
source [6, 19–26]. One example is the recently commer-
cialized multiplexed (MUX) electrospray interface,
which introduces multiple LC flows directly into a
multiplexed electrospray ion source [25, 27]. The tech-
nique has been shown to be extremely powerful for
increasing qualitative analysis throughput. A challenge
remains in developing automated data processing tools
to facilitate postdata acquisition processing of MUX-
derived ADME data. An important limitation of the
MUX technique at this time is that it is not ideally suited
to quantitative analysis because of the sampling effi-
ciency of the multiplexed sprayer assembly. As the
number of sprayers increases, the duty cycle increases,
leading to less frequent sampling at any given channel
and hence, poorer ion statistics and greater error in
mass measurements.
Our group has put great effort into developing
parallel LC/MS technology in areas of compound li-
brary analysis, high throughput mass-directed purifica-
tion, and ADME studies [19, 27–29]. In this report, an
eight-channel parallel LC/MS system and associated
VisualBasic and Applescript automated data processing
applications for in vitro microsomal stability screening
are discussed. The system was designed with easy
implementation in mind so that an existing LC/MS
system may be converted conveniently into a parallel
LC/MS system with minimal modification. An equally
important aspect of this high throughput ADME system
was the development of a number of custom Apple-
Scripts and Excel macros and templates to streamline
and automate the pre- and postanalysis processing of
massive amounts of experimental data. For example, for
every plate of samples (88 compounds  8 controls)
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requiring microsomal stability analysis, more than 1000
samples are generated, requiring sophisticated data
processing. Only with these data acquisition and post-
data acquisition processing tools is it possible to make
the system truly high throughput. The system can
analyze 240 or more samples per hour. As the first
application of the system, we developed a high
throughput microsomal metabolic stability assay proto-
col. Using this protocol we are able to generate micro-
somal stability profiles of up to 176 test compounds per
day (two microtiter plates of samples) at four time
points (t0, t5, t15, t30) and in triplicate (a total of 12
discrete samples required for analysis for each test
compound).
Experimental
Chemicals and Reagents
Acetonitrile (ACN) was obtained from J. T. Baker (Phill-
ipsburg, NJ). Dimethylsulfoxide (DMSO) was obtained
from EM Science (Gibbstown, NJ). Formic acid, trichlo-
roacetic acid (TCA), sodium phosphate, sodium hy-
droxide (NaOH), D-nicotinamide adenine dinucleotide
phosphate reduced form (NADPH), atenolol, buspirone
hydrochloride, imipramine hydrochloride, lidocaine
hydrochloride, methoxyverapamil hydrochloride, DL-
propranolol hydrochloride, ()-sulpiride, and ()-vera-
pamil hydrochloride were obtained from Sigma Chem-
ical Co. (St. Louis, MO). In these studies, pooled human
liver microsomes (HLM’s) containing 20 mg/mL of
total protein were used and obtained from Gentest
Corp. (Woburn, MA). Sodium phosphate buffer was
prepared as a 50 mM stock solution in deionized water
and adjusted with 1 M NaOH solution to pH 7.4. The
stock reference solutions (atenolol, buspirone, imipra-
mine, lidocaine, methoxyverapamil, propranolol,
sulpiride, and verapamil) were prepared at 10 mM
concentration in DMSO, then diluted to 1 mM with
ACN prior to use. NADPH solution was prepared at 4
mM concentration in phosphate buffer prior to use.
TCA solution was prepared at 0.3 M in deionized water.
The microsomes were thawed and mixed with phos-
phate buffer to give a 2 mg/mL total protein solution
before use.
High Throughput Metabolic Stability Procedure
This procedure has been applied to the metabolic sta-
bility studies of compounds in liver microsomes from
various species, including human, monkey, dog, rat,
and mouse, although only human liver microsome
experiments are described in this article. The following
procedure was applied to 96-well microtiter plate mi-
crosomal incubations, schematically represented in Fig-
ure 1. Eight reference compounds (atenolol, buspirone,
imipramine, lidocaine, methoxyverapamil, propranolol,
sulpiride, and verapamil) were incubated with 88 test
compounds in a 96-well plate. Liquid transfer steps
were performed with a PP-550 MS 96-channel Personal
Pipettor (Apricot Designs, Inc., Monrovia, CA) under
computer control. Test compounds (4 nanomoles each)
were dispensed, by aid of a Tecan Genesis Robotic
Sample Processor (Tecan, Hombrechtikon, Switzer-
land), into 88 wells of a 1.2-mL deep-well substrate
plate. Compounds were arrayed in the microtiter plate
in such a way as to leave the first column (8 wells)
empty for reference compounds. The plate was then
dried down to remove the solvent by aid of speed-vac
lyophilization (Savant, Inc., Farmingdale, NY). NADPH
solution (500 L, 4 mM) was then added to each well of
the plate to dissolve the test compounds. In some
instances, it was necessary to agitate and heat the plates
to aid in dissolution, as some compounds do not readily
dissolve in the NADPH buffer solution. Solutions of
eight reference compounds (4 L 1mM) were added
into the first column of the microtiter plate. The solu-
tions in the plate were then transferred into twelve 200
L low volume incubation plates (30 L each well). The
incubation plates and the microsomes plate (2 mg/mL
total protein) were preheated at 37 °C for 5 min in a
VWR incubator (VWR Scientific Products, Cornelius,
OR). The 2 mg/mL microsomes solution was then
added into all wells of the incubation plates (30 L/
well). The final incubation solutions contain 4 M test
compound or reference compound, 2 mM NADPH, 1
mg/mL (total protein) microsomes, 50 mM phosphate
(pH 7.4). The incubation plates were then incubated at
37 °C for 0, 5, 15, and 30 min, respectively. At each time
point, three incubation plates were removed from the
incubator and quenched immediately.
Several different solvents were evaluated for
quenching the microsomal stability incubations. Typi-
cally, acetonitrile is added in equal or excess volume to
the microsomal incubate (i.e., NADPH buffer solution
containing microsomes) to quench the reaction and
precipitate proteinaceous material. However, it was
found that a significant number of the test compounds
eluted in the solvent front upon injection onto the short
C18 analytical columns. It was found that an equal
volume of aqueous 0.3 M TCA was effective at quench-
ing the enzyme activity and precipitating the proteins.
Figure 1. High throughput microsomal stability experiment pro-
cedure conducted in 96-well plate format. Each plate of test
compounds yields twelve plates of analysis samples when the
experiment is conducted in triplicate at four time points (0, 5, 15,
30 min).
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This solution also drastically reduced the number and
amount of test compounds eluting in the void volume.
A number of control samples were evaluated for chem-
ical stability in the presence of this 50/50 NADPH
buffer/TCA solution and none were found to have
degraded. Therefore, 60 L of 0.3M TCA was added to
each well to quench the reaction. The quenched plates
were centrifuged for 15 min in a SpeedVac Plus centri-
fuge. The supernatants were then transferred to new
200 L low volume analytical plates for high through-
put parallel LC/MS.
High Throughput Parallel LC/MS
The high throughput parallel LC/MS system shown
in Figure 2 consists of two Shimadzu LC10ADvp
Solvent Delivery pumps, an SCL-10Avp System Con-
troller (Shimadzu Corp. Columbia, MD), a Gilson 215
multiple probe autosampler (8-channel) (Gilson, Inc.,
Madison, WI), a Valco switching valve (Valco Instru-
ments Co. Inc., Houston, TX), and an Applied Biosys-
tems/MDS-SCIEX API165 single quadrupole mass
spectrometer equipped with a TurboIonSpray ion
source (AB/MDS-SCIEX, Foster City, CA). The au-
tosampler has eight needles spaced to fit eight wells
of a standard 96-well microtiter plate. Eight samples
are injected into the eight injection ports simulta-
neously and onto eight separate microbore columns.
The volume of the sample loops is 20 L and full loop
injections were used for all experiments. A total
mobile phase flow rate of 2.0 mL/min was used and
split into eight equivalent streams using a Valco
manifold before entering the multiple probe au-
tosampler. Eight microbore columns (10 mm  1 mm
i.d., 3 m, HQ-C18, Peeke Scientific, Redwood City,
CA) were connected to eight injection valves of the
autosampler (flow rate 0.25 mL/min for each col-
umn). The outlets of the columns were recombined
using a second Valco manifold. The flow was then
passed through a Valco flow divert valve before
entering the mass spectrometer. The in-line flow
divert valve was used to ensure that undesirable
materials eluted at the solvent front would be di-
verted to waste to keep the ion source from becoming
contaminated. When the valve was in the sampling
position, the mobile phase was passed directly into
TurboIonSpray ion source without splitting. The ion
source was maintained at 350 °C to ensure sufficient
desolvation of the liquid droplets in the ion source at
the total 2 mL/min flow rate. The mobile phase
solvents used in this study were (A) 0.04% formic
acid in water; and (B) 0.04% formic acid in acetoni-
trile. The following mobile phase gradient was ap-
plied: 1% B hold for 0.3 min; 1–25% B in 0.05 min;
hold at 25% B for 0.1 min; 25–70% B in 0.4 min; hold
at 70% B for 0.4 min. The switching valve was set to
divert flow to waste for the first 0.25 min of the
gradient. The columns were reequilibrated at starting
conditions while the next set of samples was injected.
Two computers were used to acquire microsomal
stability data. The AB/MDS-SCIEX API165 mass
spectrometer was controlled by a G3 Power Macin-
tosh and associated MassChrom 1.2 software. The
autosampler was controlled by a PC with UniPoint
software (Gilson, Inc., Madison, WI). The two com-
puters communicated with each other through con-
tact closures for synchronized operation. The mass
spectrometer was configured to acquire data in se-
lected ion monitoring (SIM) mode, allowing eight
ions to be monitored during each scan (dwell time 50
Figure 3. ADME 8 SIM Data Processing script batch processes
LC/MS data using an intelligent algorithm to ensure the peaks of
interest are integrated consistently and correctly. It extracts and
integrates all SIM chromatograms in each file and writes the
integration results to an output file that is then imported into Excel
templates for final report generation.
Figure 2. High throughput eight-channel parallel LC/MS system
consisting of Shimadzu gradient HPLC pumps, a Gilson 215
multiple probe autosampler, an AB/MDS-SCIEX API165 Mass
Spectrometer equipped with a TurboIonSpray ion source, eight
Peeke Scientific microbore columns (10 mm  1 mm i.d., 3 m,
HQ-C18), and a Valco switching valve. The volume of the sample
loops is 20 L and full loop injections were used for all experi-
ments. Total mobile phase flow rate is 2.0 mL/min (0.25 mL/min
for each column). The flow is diverted to waste by a Valco
switching valve in the early part of the gradient.
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ms for each ion). The SIM values were defined in the
job list of the MassChrom 1.2 Sample Control data
acquisition sheet. All data were acquired in the
positive ionization mode. The instrument resolution
was set to 1500 (10% valley definition) based on the
infusion of a (poly)propylene glycol calibrant solu-
tion.
Scripts and Macros are Critical to Successful High
Throughput ADME Analyses
Several custom AppleScripts, Excel macros, and Excel
templates were designed and developed to facilitate
both pre- and postanalysis processing in order to take
full advantage of this system for high throughput
Figure 4. An example of the selected ion monitoring chromatograms from the eight-column parallel
analysis. The trace of each compound was extracted from the total ion chromatogram by the ADME
8 SIM Data Processing script. (a) Verapamil, (b) propranolol, (c) imipramine, (d) lidocaine, (e)
sulpiride, (f) atenolol, (g) buspirone, (h) methoxyverapamil, and (i) total ion chromatogram of all eight
compounds.
Figure 5. Assessment of intra-column performance in parallel mode of operation. Each compound
(0.5 M) is injected onto a unique column with 500 repeat injections over a period of 17 h. The
coefficient of variations (CV) of retention times and mass spectrometric peak areas for all of the eight
columns are below 2% (average 0.9%) and 10% (average 5.7%), respectively. (a) Peak areas and (b)
retention times.
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microsomal stability assays. The first of these was a
FormatPlate Excel macro. The macro first compares SIM
values of each of the test compounds in the set. Next, it
arranges the compounds in appropriate wells such that
the molecular weights are no closer than three Da from
one another (obviating the need for indexed MUX
analysis). For almost all compounds evaluated, this 3
Da window has been satisfactory. In those instances
where a compound was found to contain more than one
chlorine and/or bromine atom, a larger mass Da win-
dow between samples was used. A FormatSampleCon-
trol macro generates a job list for Sample Control to
execute the LC/MS analysis. For data processing, an
ADME 8 SIM Data Processing script (Figure 3) was
developed. The script launches MultiView, opens each
data file, extracts and integrates all SIM chromatograms
in each file and writes the integration results to an
output file that is imported into Excel templates for final
report generation. An algorithm in the ADME 8 SIM
Data Processing script was also developed to ensure the
peaks of interest are integrated consistently and cor-
rectly, as will be discussed shortly. A StabilityReport
macro was developed to import the validated integra-
tion result file into an Excel Report Template and
automatically generate a report with plots, final results,
and data quality evaluations. Features of these scripts
and macros are discussed below.
Results and Discussion
Intra- and Inter-Column Retention Times and Peak
Area Variation Among the Eight Columns
Much discussion has ensued as to whether an HPLC
system can be conveniently converted from serial mode
Figure 6. Assessment of inter-column variability of retention times and peak areas using eight
parallel columns and a binary pumping system with a precolumn flow splitter. A solution containing
0.5 M of the eight reference compounds was injected sequentially onto each of the eight columns
while the remaining seven columns received blank injections. The data of five replicate injections
show that the coefficient of variations (CV) of retention times and peak areas among the eight columns
are below 2% (average 0.5%) and 10% (average 3.6%), respectively. (a) Retention times and (b) peak
areas.
Figure 7. Linear correlation of the peak areas with sample
concentrations in the range from 0.05 to 5 M (injection volume:
20 L). Each concentration was injected in triplicate. The linear
correlation curves were excellent between 0.05 and 2.5 M for all
eight references and could be extended to 5 M or above for most
of the compounds. (a) Atenolol, (b) buspirone, (c) imipramine, (d)
lidocaine, (e) methoxyverapamil, (f) propranolol, (g) sulpiride,
and (h) verapamil.
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to parallel mode without sophisticated pumping and
flow control. In our laboratory, successful parallel ana-
lytical LC/MS has been achieved using a simple valco
manifold to split the flow from a binary HPLC system
evenly between eight columns. Approximately 100,000
samples have been analyzed in this parallel configura-
tion for early ADME assessment successfully.
A series of experiments were conducted to test the
intra-column variation when operated in the parallel
mode. System performance was evaluated using the
eight reference compounds: atenolol (m/z 267.2), buspi-
rone (m/z 386.2), imipramine (m/z 281.2), lidocaine (m/z
235.2), methoxyverapamil (m/z 485.3), propranolol (m/z
260.2), sulpiride (m/z 342.1), and verapamil (m/z 455.3).
Eight solutions containing 0.5 M of each individual
reference compound were prepared and injected onto
the eight columns simultaneously. The experiment was
performed over a period of 17 h with a total of 500
repeat injections. An example of the eight chromato-
grams from the eight column parallel analysis is shown
in Figure 4. The data show that the coefficient of
variations (CV) of retention times and mass spectromet-
ric peak areas for all of the eight columns are below 2%
(average 0.9%) and 10% (average 5.7%), respectively
(Figure 5).
To assess inter-column variation, a solution contain-
ing 0.5 M of the eight reference compounds was
prepared and injected sequentially onto each of the
eight columns while the remaining seven columns
received blank injections. A total of five replicate injec-
tions was made. The data for the eight reference com-
pounds show that the coefficient of variations (CV) of
retention times and peak areas among the eight col-
umns are below 2% (average 0.5%) and 10% (average
3.6%), respectively (Figure 6). This data shows that the
valco flow splitter is effective at providing equal flows
to each of the eight columns.
Linear Correlation of the Peak Areas with
Sample Concentrations
Standard solutions of the eight reference compounds
were prepared at eight concentrations in the range from
0.05 to 5 M (injection volume: 20 L). Each concentra-
tion was injected in triplicate. The linear correlation
curves were excellent between 0.05 and 2.5 M for all
eight references and could be extended to 5 M or
above for most of the compounds (Figure 7). It was
assumed that similar linear correlations would be ob-
served for the test compounds and that there was
therefore no need to construct individual calibration
curves for each of the test compounds. Instead, the
relative percent remaining of the parent compounds
was calculated by directly comparing samples at each
time point (t5, t15, and t30) to its initial time point (t0).
High Throughput Microsomal Stability Profiling of
Compound Libraries
High throughput microsomal stability experiments of
project compounds are performed without any prean-
alysis or prequalification in order to ensure rapid turn-
around to the project teams. For each plate of test
compounds, more than one thousand samples are gen-
erated for LC/MS analysis. In the absence of automated
data processing tools, the postanalysis data reduction
and validation processes would be exceedingly tedious.
To address this data management problem, a Stability-
Report macro was developed to automate these tasks.
The macro imports the integration result file, deconvo-
lutes the eight-channel results, and generates stability
plots for each compound as well as a summary report
for the whole plate. The macro then further analyzes
and validates the results of each compound, generating
a flag for any compound that has incorrect stability
trend, low MS signal, or broad chromatographic peak.
With this intelligent validation tool, the postanalysis
data processing time is automatically reduced from
about one day per plate (manually) to literally minutes
per plate. A sample plot of the eight reference standards
is shown in Figure 8. Buspirone, methoxyverapamil,
and verapamil showed fast turnover; imipramine, lido-
Figure 8. Microsomal stability profiles of eight reference com-
pounds. (a) Atenolol, (b) buspirone, (c) imipramine, (d) lidocaine,
(e) methoxyverapamil, (f) propranolol, (g) sulpiride, and (h)
verapamil. Buspirone, methoxyverapamil, and verapamil showed
fast turnover; imipramine, lidocaine, and propranolol intermedi-
ate; and atenolol and sulpride slow.
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caine, and propranolol intermediate; and atenolol and
sulpiride slow.
As can be seen from the data in Figure 8, the amount
of parent remaining at the end of a microsomal incuba-
tion may be very high or very low, depending on
whether or not the compound is a substrate for the
cytochrome P450 enzymes. For example, buspirone and
verapamil (Figure 8b and h respectively) exhibit less
than 5% parent remaining after a 30 min incubation. At
an initial substrate concentration of 2 M, 5% remaining
corresponds to a concentration of 0.1 M (or 100
femtomole/L concentration). At this concentration,
the chromatographic peak of interest very often may
not be integrated properly. The low intensity peaks can
be affected by baseline noise and result in improper
integration. To address this problem, an algorithm in
the ADME 8 SIM Data Processing script was developed
to ensure the peaks of interest are integrated consis-
tently and correctly. Files were named systematically so
that the script recognizes all files corresponding to the
same set of compounds. The script uses MassChrom’s
integration tool to obtain the retention times at the start
of the peak, the apex of the peak, and at the end of the
peak, specifically for the t0 time-point for each set of
compounds. Since the t0 time-point contains the most
amount of parent and gives the strongest ion intensity,
the script applies these start, end, and peak max values
to the remaining time-points automatically. If the peak
apex moves in this narrowly defined time range be-
cause of slight chromatographic condition changes, the
Figure 9. A partial microsomal stability summary report of a plate of eight reference compounds and
88 test compounds received from a drug discovery project and tested without any preanalysis or
prequalification. The percent remaining values of the parent compounds were colored for easy
visualization: Green, 80%; yellow, 80–40%; red, 40%; gray, flagged by the intelligent validation
macro.
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script will automatically apply an offset to the integra-
tion window so that the peak is integrated properly.
Since the integration is performed in a fixed window
determined by the script for each compound, Multiv-
iew’s integration tool can not be used. The script uses its
own integration routine that integrates the area point by
point after subtracting the background. This integration
routine was validated against Multiview’s integration
tool using the same integration window and gave
similar results.
A microsomal stability partial summary report of a
plate of 8 reference compounds and 88 test compounds
received from a drug discovery project and tested
without any preanalysis or prequalification is shown in
Figure 9. The percent remaining values of the parent
compounds were color-coded for easy visualization:
Green, 80%; yellow, 80–40%; red, 40%; gray,
flagged by the intelligent validation macro. Figure 10
shows a report page of the microsomal stability profiles
of eight test compounds. Compounds D, F, and G
showed fast turnover, Compound E intermediate, and
Compounds B and H slow. As identified by the intelli-
Figure 10. A microsomal stability report of eight test compounds received from a drug discovery
project and tested without any preanalysis or prequalification. Compounds D, F and G showed fast
turnover; Compound E intermediate; and Compounds B and H slow. As identified by the intelligent
validation macro and noted next to the plots, Compound A did not yield a profile because of low ion
intensity, and Compound C showed a poor stability trend.
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gent validation macro and noted next to the plots,
Compound A did not yield a profile due to low ion
intensity and Compound C showed a poor stability
trend. The project chemist receives both the summary
report which helps “bin” the compounds into distinct
classes of microsomal stability and the time-course
stability plots for all compounds submitted for HT
microsomal stability analysis. This information helps
the chemists prioritize compounds for further consid-
eration as potential drug candidates.
Conclusions
An eight-channel parallel LC/MS system was pre-
sented for high throughput analysis of compound li-
braries for microsomal stability, permitting up to 240
samples to be analyzed per hour. The high throughput
system was shown to perform exceedingly well in terms
of reproducibility and robustness. Only very small
column to column variations of retention times and
peak areas were observed. The linear range was satis-
factory for the microsomal stability experiments de-
scribed in this article (maximum concentration 2 M).
The system is easily modified for parallel operation on
existing LC/MS instruments requiring only minimal
hardware modifications and has been applied success-
fully to the microsomal stability profiling of over 10,000
project compounds.
Acetonitrile is the most commonly used solvent for
quenching and precipitating the microsomal incuba-
tions. However, we found that a number of compounds
dissolved in 50/50 NADPH/acetonitrile buffer eluted
in the solvent front upon injection onto the 10 mm  1
mm i.d. C18 columns. TCA, on the other hand, was
found effective at quenching the microsomal incuba-
tions while enabling compounds to be retained on
column. A potential problem with using an acid as a
quench solution is that the compounds may undergo
chemical degradation. None of our standards was
found to degrade in the presence of this TCA solution.
One way to confirm that none of the test compounds is
degraded when exposed to this TCA quenching solu-
tion is to incubate the test compounds in the absence of
NADPH, a cofactor required for enzymatic activity).
The relative response of the test compound in the
presence/absence of NADPH would allow one to
readily decouple chemical stability from microsomal
stability.
It is assumed that positive electrospray ionization
detection and our so called universal gradient are
satisfactory for the vast majority of compounds con-
tained within the library. In reality, we observe on
average a 65–70% success rate. The majority of failures
are attributable to weak ion intensities, poor compound
solubility, and/or experimental pipetting or injection
errors. Of these three, solubility appears to have the
greatest impact on the success rate to date. Additional
limitations of this system are mainly (1), signal reduc-
tion due to recombination of eight streams, and (2),
mass separation requirement in the same set of injec-
tions. The former is not a problem for in vitro ADME
assays of most pharmaceutical compounds but does
sometimes cause quantification difficulty for poorly
ionizable compounds. The latter has to be handled in
the sample submission step to ensure test compounds
are plated properly. With further development, MUX
electrospray interfaces that introduce multiple LC flows
directly into ion sources and employ indexing to differ-
entiate individual channels may eliminate some of the
above limitations and further improve the success rate
and the workflow efficiency.
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